Botulinum Toxin for the Treatment of Sialorrhea

Vashishta, Rishi; Nguyen, Shaun A.; White, David R.; Gillespie, M. Boyd

doi:10.1177/0194599812465059

Cited by 70 publications

(49 citation statements)

References 26 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent meta‐analysis from eight randomized placebo‐controlled trials of BTX injection in other diseases showed that common side effects included increased saliva thickness (3.9%), dysphagia (3.3%), xerostomia (3.3%), and pneumonia (2.2%) 21. Although our patients did not experience any adverse reaction related to BTXA, dysphagia could not be evaluated due to tube feeding resulting from decreased mentality.…”

Section: Discussionmentioning

confidence: 73%

Botulinum toxin treatment for hypersalivation in anti‐NMDA receptor encephalitis

Jun

Seo

Lee

et al. 2017

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Hypersalivation is one of the intractable symptoms of anti‐N‐methyl‐d‐aspartate receptor (NMDAR) encephalitis. While anticholinergic medications partially improve the hypersalivation, they can aggravate the autonomic dysfunctions associated with anti‐NMDAR encephalitis. Thus, we investigated the efficacy and safety of botulinum toxin type A injection on hypersalivation refractory to anticholinergics in six patients with anti‐NMDAR encephalitis. Hypersalivation was well‐controlled without remarkable adverse reaction over 16 weeks after botulinum toxin type A, although two patients were reinjected at 12 weeks due to reaggravation of hypersalivation. Our findings suggest that botulinum toxin type A might be a better choice than anticholinergics for management of hypersalivation in patients with anti‐NMDAR encephalitis.

show abstract

Section: Discussionmentioning

confidence: 73%

Botulinum toxin treatment for hypersalivation in anti‐NMDA receptor encephalitis

Jun

Seo

Lee

et al. 2017

Ann Clin Transl Neurol

View full text Add to dashboard Cite

show abstract

“…10,13 When injected into the salivary gland, it blocks the release of acetylcholine at the cholinergic neurosecretory junction 13,29. Reinnervation occurs over several months as new neuroglandular junctions are created 3…”

Section: Management Optionsmentioning

confidence: 99%

“…Another systematic review included four RCTs in children (all included in the other two reviews), involving a total of 103 children 10. The review reported a significant improvement in drooling severity in children at 4 weeks (standardised mean difference –1.84, 95% CI –2.67 to –1.00) 10.…”

Section: Management Optionsmentioning

confidence: 99%

See 1 more Smart Citation

Challenges in managing drooling in children

2015

DTB

View full text Add to dashboard Cite

Drooling is the unintentional loss of saliva from the mouth, either anteriorly (visible) or posteriorly (with a risk of coughing, vomiting, aspiration and chronic respiratory disorders).(1,2) Anterior drooling is normal in infancy, but is considered neuro-developmentally abnormal if it occurs in children over the age of 4 years old, and is commonly seen in those with physical, intellectual and learning disability, and poor neuromuscular coordination and oral control.(1,3-7) For example, drooling occurs in 10-38% of children with cerebral palsy.(6,8) Drooling is usually due to failure to clear saliva rather than hyper-salivation (sialorrhoea), and a head-down posture and sucking on fingers or clothing may be contributory factors.(1,2,5-7) Here we review the challenges associated with the management of drooling in children.

show abstract

“…aufrechterhalten werden. Im aktuellen interdisziplinären Konsensus hat sich die Injektion von Botulinumtoxin in die Kopfspeicheldrüsen etabliert [1,2] 11 Behandlungen darunter. In der Gesamtbetrachtung aller 117 Behandlungen lag der Anteil mit "gut" ("gut" sowie "gerne mehr") bewertetem Therapieansprechen in der Standarddosis bei 51 % (90 %), in der niedriger dosierten Gruppe bei 65 % (88 %) und in der höher dosierten Gruppe bei 73 % (95 %).…”

unclassified

Botulinumtoxin bei funktioneller Hypersalivation – alles eine Frage der Dosis?

et al. 2014

View full text Add to dashboard Cite

Botulinum toxin injection as a treatment of hypersalivation is an effective method with only minor side effects, even in increased dosage levels. Nevertheless, certain modifications according to each individual treatment are required. Possible side effects such as swallowing problems or non-responding situations should always be part of informed consent, especially as the latter is even possible for higher dosage levels.

show abstract

Botulinum Toxin for the Treatment of Sialorrhea

Abstract: Botulinum toxin is a clinically effective therapy that improves drooling severity in patients with sialorrhea. Future studies will need to further evaluate the technique and examine dosages required to achieve optimal outcomes.

Cited by 70 publications

References 26 publications

Botulinum toxin treatment for hypersalivation in anti‐NMDA receptor encephalitis

Botulinum toxin treatment for hypersalivation in anti‐NMDA receptor encephalitis

Challenges in managing drooling in children

Botulinumtoxin bei funktioneller Hypersalivation – alles eine Frage der Dosis?

Contact Info

Product

Resources

About